EMVision is broadening its emu™ Pivotal Trial to include acute ischaemia detection, aiming to accelerate FDA clearance and enhance the brain scanner's clinical impact. Recruitment has passed 125 patients across US and Australian sites, with full enrolment expected by early 2027.
- Acute ischaemia detection added to pivotal trial
- Over 125 patients enrolled across eight hospitals
- FDA pre-submission engagement planned for endpoint expansion
- Regional Benefit Study progressing with government funding
- Strong cash reserves support ongoing clinical programs
Trial Expansion Targets Broader Stroke Diagnosis
EMVision Medical Devices (ASX:EMV) is ramping up its emu™ Pivotal (Validation) Trial by incorporating acute ischaemia detection alongside haemorrhage identification. This strategic move aims to streamline regulatory approval by validating both critical stroke types simultaneously, potentially shaving up to two years and millions in trial costs. The addition significantly expands the device’s clinical utility, given that ischaemic strokes account for approximately 80% of all cases.
The company plans to engage the FDA soon in a pre-submission meeting to align on the expanded endpoint, clinical claims, and performance thresholds. This approach leverages existing patient cohorts and infrastructure, avoiding the need for a separate trial. As EMVision CEO Scott Kirkland noted, this shift represents a “step-change” for the emu™ Brain Scanner, enhancing commercial prospects from the first FDA release.
Recruitment Momentum Across US and Australian Sites
The pivotal trial has passed a key milestone with over 125 patients enrolled across eight leading stroke centres in the United States and Australia. These include prestigious institutions such as Mayo Clinic Florida, Mt Sinai Hospital New York, Ronald Reagan UCLA Medical Center, and Royal Melbourne Hospital. Recruitment acceleration initiatives, including broader clinical team engagement and extended after-hours coverage, are expected to further boost enrolment rates.
Princess Alexandra Hospital in Queensland, currently part of the Continuous Innovation Study, is transitioning into the pivotal trial, capitalising on trained staff and site readiness. EMVision is also evaluating additional US stroke centres referred to the company, reflecting growing clinical interest in the emu™ technology. The trial aims to enrol 300 suspected stroke patients, split evenly between intracranial haemorrhage and other stroke types, with full enrolment anticipated by late 2026 or early 2027.
Clinical and Commercial Implications of Ischaemia Detection
Detecting acute ischaemia at the bedside is a complex challenge, particularly in hyperacute care settings lacking advanced neuroimaging. EMVision’s technology is designed to fill this diagnostic gap, enabling faster triage and treatment decisions that could reduce intervention delays and improve patient outcomes. Every minute saved in the door-to-thrombectomy pathway preserves brain tissue and enhances functional recovery.
Validating ischaemia detection also lays groundwork for EMVision’s next-generation First Responder device, intended for pre-hospital environments. This could broaden the company’s addressable market and position the emu™ Brain Scanner as a versatile tool across the stroke care continuum.
Supporting Studies and Funding Provide Strong Backdrop
Alongside the pivotal trial, the emu™ Continuous Innovation Study continues to refine algorithms and develop new features, with enrolment exceeding 100 patients. The Regional Benefit Study, funded by a $3 million Australian government grant, is progressing towards deploying the scanner in underserved regional settings, aiming to reduce diagnostic delays via telehealth integration.
EMVision remains financially robust, holding $18.4 million in cash reserves as of March 2026, supplemented by $6.2 million in remaining non-dilutive funding. This strong capital position underpins ongoing clinical activities and commercialisation efforts. The company’s recent initiatives build on earlier momentum, including the eight hospitals actively recruiting and the $3.8 million R&D tax refund that bolstered its financial runway.
EMVision’s clinical program is gathering pace, with sequential cohort readouts expected shortly after full enrolment. The market will be watching closely as the company navigates FDA engagement and delivers data that could redefine point-of-care stroke diagnostics.
Bottom Line?
EMVision’s trial expansion to include acute ischaemia detection could accelerate regulatory approval and broaden clinical impact, but FDA acceptance and trial outcomes remain pivotal uncertainties.
Questions in the middle?
- How will the FDA respond to the proposed ischaemia endpoint expansion?
- Can recruitment acceleration sustain momentum to meet late 2026 enrolment targets?
- What impact will ischaemia detection validation have on commercial adoption timelines?